Most Popular
-
1
Yoon's approval rating plunges to all-time low
-
2
Climate impacts set to cut 2050 global GDP by nearly a fifth
-
3
S. Korea votes in favor of Palestinian bid for UN membership
-
4
Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official
-
5
Bae Doo-na shares portraying Korean identity in Hollywood's 'Rebel Moon'
-
6
[From the Scene] Monks, Buddhists hail return of remains of Buddhas
![[From the Scene] Monks, Buddhists hail return of remains of Buddhas](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/19/20240419050617_0.jpg&u=20240419175937)
-
7
Medical schools granted enrollment quota flexibility for next year
-
8
Korean art gets spotlight at Venice Biennale 2024
-
9
Police uncover illegal gambling website made by teens, for teens
-
10
Yoon's approval rating sinks to all-time low following election loss
![[From the Scene] Monks, Buddhists hail return of remains of Buddhas](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/19/20240419050617_0.jpg&u=20240419175937)
Samsung Bioepis’ diabetes treatment under FDA review for sale
By 최희석Published : Aug. 8, 2016 - 17:06
[THE INVESTOR] The US Food and Drug Administration has begun reviewing the diabetes treatment SB9 for sale in the US, local media reported on Aug. 8.
SB9, developed by MSD in collaboration with Samsung Bioepis, is a biosimilar of Lantus developed by Sanofi.
Samsung Bioepis is an affiliate of Korean tech giant Samsung Electrioncs.
According to reports, SB9 could be approved for sale by the end of next year.
Including SB9, Samsung Bioepis has six biosimilar products in the works. Of the six, two treatments for autoimmune conditions have been approved in South Korea and Europe.
By Choi He-suk (cheesuk@heraldcorp.com)
SB9, developed by MSD in collaboration with Samsung Bioepis, is a biosimilar of Lantus developed by Sanofi.
Samsung Bioepis is an affiliate of Korean tech giant Samsung Electrioncs.
According to reports, SB9 could be approved for sale by the end of next year.
Including SB9, Samsung Bioepis has six biosimilar products in the works. Of the six, two treatments for autoimmune conditions have been approved in South Korea and Europe.
By Choi He-suk (cheesuk@heraldcorp.com)
![[From the Scene] Monks, Buddhists hail return of remains of Buddhas](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/19/20240419050617_0.jpg&u=20240419175937)
![[KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/18/20240418050645_0.jpg&u=20240419100350)
![[Today’s K-pop] Illit drops debut single remix](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=642&simg=/content/image/2024/04/19/20240419050612_0.jpg&u=)